Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 26,831 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 26,831 shares of the stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $23.09, for a total transaction of $619,527.79. Following the transaction, the insider directly owned 18,869,229 shares in the company, valued at $435,690,497.61. This trade represents a 0.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Roivant Sciences Stock Performance

Roivant Sciences stock traded up $0.62 during midday trading on Friday, reaching $22.41. The stock had a trading volume of 14,906,601 shares, compared to its average volume of 7,509,639. The company has a fifty day moving average price of $20.00 and a two-hundred day moving average price of $15.07. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $23.47.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Jefferies Financial Group raised their price objective on shares of Roivant Sciences from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, September 18th. Guggenheim reiterated a “buy” rating and set a $28.00 price target on shares of Roivant Sciences in a research note on Thursday. Weiss Ratings raised Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a report on Saturday, October 25th. Citigroup raised their target price on Roivant Sciences from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Finally, Bank of America upped their price target on Roivant Sciences from $12.00 to $16.50 and gave the stock a “neutral” rating in a report on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Roivant Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $25.19.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ROIV. Allworth Financial LP raised its holdings in shares of Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares during the period. Swiss Life Asset Management Ltd bought a new stake in Roivant Sciences in the 3rd quarter valued at about $217,000. Danske Bank A S purchased a new stake in Roivant Sciences during the third quarter valued at about $138,000. XTX Topco Ltd purchased a new stake in shares of Roivant Sciences during the 3rd quarter valued at approximately $1,067,000. Finally, Alyeska Investment Group L.P. raised its holdings in Roivant Sciences by 326.7% during the 3rd quarter. Alyeska Investment Group L.P. now owns 494,455 shares of the company’s stock valued at $7,481,000 after acquiring an additional 378,589 shares during the period. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.